Press Releases

Press Releases

Aug 05, 2024

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

May 29, 2024

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

May 23, 2024

CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments

May 09, 2024

CRISPR Therapeutics to Present at the Bank of America Securities Health Care Conference

May 08, 2024

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

May 08, 2024

CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing Approach

Apr 22, 2024

CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

Apr 03, 2024

CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference

Apr 01, 2024

CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

Mar 13, 2024

CRISPR Therapeutics Proposes New Appointment to the Board of Directors

Feb 21, 2024

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 15, 2024

CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit

Feb 13, 2024

CRISPR Therapeutics Announces $280 Million Registered Direct Offering

Feb 13, 2024

European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)

Jan 16, 2024

CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia

Jan 08, 2024

CRISPR Therapeutics Highlights Strategic Priorities and 2024 Outlook

Jan 03, 2024

CRISPR Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 08, 2023

Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease

Dec 04, 2023

CRISPR Therapeutics Announces Updates to Immuno-Oncology Pipeline and Expansion into Autoimmune Disease

Nov 16, 2023

Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Nov 06, 2023

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

Nov 06, 2023

CRISPR Therapeutics Announces Preclinical Data at the American Heart Association (AHA) Scientific Sessions 2023

Oct 31, 2023

CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel (exa-cel) for Severe Sickle Cell Disease

Oct 31, 2023

CRISPR Therapeutics Trading Halted Today; FDA Advisory Committee to Review Biologics License Application (BLA) for Exagamglogene Autotemcel (exa-cel) in Sickle Cell Disease (SCD)

Oct 16, 2023

CRISPR Therapeutics Proposes New Appointment to the Board of Directors

Sep 27, 2023

CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Sep 07, 2023

CRISPR Therapeutics Announces Leadership Transition

Aug 30, 2023

CRISPR Therapeutics to Participate in Citi's 18th Annual Biopharma Conference

Aug 07, 2023

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results

Jun 13, 2023

CRISPR Therapeutics to Participate in Goldman Sachs 44th Annual Global Healthcare Conference

Jun 09, 2023

Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress

Jun 08, 2023

FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

May 08, 2023

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results

May 02, 2023

CRISPR Therapeutics to Participate Upcoming Investor Conferences

Apr 13, 2023

CRISPR Therapeutics to Participate in Needham’s 22nd Annual Healthcare Conference

Apr 03, 2023

CRISPR Therapeutics and Vertex Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Mar 29, 2023

CRISPR Therapeutics Announces Departure of Board Member

Mar 27, 2023

CRISPR Therapeutics and Vertex Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes

Mar 14, 2023

CRISPR Therapeutics to Present at the American Association for Cancer Research 2023 Annual Meeting

Mar 13, 2023

CRISPR Therapeutics Announces Transition of Chief Financial Officer

Feb 27, 2023

CRISPR Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference

Feb 21, 2023

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Feb 08, 2023

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Jan 11, 2023

CRISPR Therapeutics to Participate in B. Riley Securities’ 3rd Annual Oncology Conference

Dec 19, 2022

CRISPR Therapeutics Announces the Appointment of Alex Harding, M.D., M.B.A., as Head of Business Development

Dec 12, 2022

CRISPR Therapeutics Provides Update on Its Ongoing Phase 1 CARBON™ Trial of CTX110®

Dec 10, 2022

CRISPR Therapeutics and Vertex to Present at the American Society of Hematology (ASH) Annual Meeting and Exposition

Dec 01, 2022

CRISPR Therapeutics to Present at the 2022 BMO Growth & ESG Conference

Nov 10, 2022

CRISPR Therapeutics Presents Data at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Nov 03, 2022

CRISPR Therapeutics Announces Poster Presentation on CTX110® at the American Society of Hematology (ASH) 2022 Annual Meeting

Nov 01, 2022

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results

Oct 27, 2022

CRISPR Therapeutics Announces Planned Transition of Chief Operating Officer

Oct 05, 2022

CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Sep 29, 2022

CRISPR Therapeutics to Present at the BMO Biopharma Spotlight Series: Gene Editing and Therapy

Sep 28, 2022

CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130™ for the Treatment of Cutaneous T-Cell Lymphomas (CTCL)

Sep 27, 2022

CRISPR Therapeutics and Vertex Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022

Aug 31, 2022

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Aug 08, 2022

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results

Jun 11, 2022

CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT™-LYM Trial of CTX130™ in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress

Jun 11, 2022

Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress

Jun 08, 2022

CRISPR Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

Jun 02, 2022

Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001™ at the 2022 Annual European Hematology Association (EHA) Congress

May 31, 2022

CRISPR Therapeutics to Host Innovation Day on June 21, 2022

May 16, 2022

CRISPR Therapeutics Announces the Appointment of Phuong Khanh Morrow, M.D., FACP, as Chief Medical Officer

May 12, 2022

CRISPR Therapeutics Announces Oral Presentation of New Clinical Data on Anti-CD70 Allogeneic CAR-T Therapy CTX130™ for Patients with T-cell Lymphoma at the Annual European Hematology Association (EHA) 2022 Hybrid Congress

May 09, 2022

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results

May 04, 2022

CRISPR Therapeutics to Present at the 2022 Bank of America Healthcare Conference

Apr 12, 2022

CRISPR Therapeutics Proposes New Appointment to the Board of Directors

Apr 07, 2022

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Mar 08, 2022

CRISPR Therapeutics Announces Poster Presentation at the American Association for Cancer Research 2022 Annual Meeting

Feb 28, 2022

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Feb 15, 2022

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

Feb 09, 2022

CRISPR Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

Feb 02, 2022

CRISPR Therapeutics and ViaCyte, Inc. Announce First Patient Dosed in Phase 1 Clinical Trial of Novel Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes (T1D)

Nov 23, 2021

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Nov 22, 2021

CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX110™ for the Treatment of Relapsed or Refractory CD19+ B-cell malignancies

Nov 16, 2021

CRISPR Therapeutics and ViaCyte, Inc. to Start Clinical Trial of the First Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes

Nov 03, 2021

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results

Nov 02, 2021

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Oct 14, 2021

CRISPR Therapeutics Announces Transition of Chief Financial Officer

Oct 12, 2021

CRISPR Therapeutics Reports Positive Results from its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell malignancies

Oct 05, 2021

CRISPR Therapeutics to Host Virtual Event Highlighting CTX110™ Clinical Data

Oct 01, 2021

CRISPR Therapeutics to Present Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

Sep 28, 2021

CRISPR Therapeutics to Participate in the Chardan’s 5th Annual Genetic Medicines Conference

Aug 05, 2021

CRISPR Therapeutics to Participate in the Canaccord Genuity 41st Annual Growth Conference

Jul 29, 2021

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results

Jun 15, 2021

CRISPR Therapeutics and Capsida Biotherapeutics Announce Strategic Collaboration to Develop Gene-Edited Therapies for Amyotrophic Lateral Sclerosis and Friedreich’s Ataxia

Jun 11, 2021

Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at European Hematology Association Annual Meeting

May 25, 2021

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

May 12, 2021

Vertex and CRISPR Therapeutics to Present New Clinical Data on Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ For Severe Hemoglobinopathies at the Annual European Hematology Association Virtual Congress

May 06, 2021

CRISPR Therapeutics and Nkarta Announce Global Collaboration to Develop Gene-Edited Cell Therapies for Cancer

Apr 29, 2021

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Apr 28, 2021

CRISPR Therapeutics Announces Trials in Progress Poster Presentation at the 2021 American Society of Clinical Oncology Annual Meeting

Apr 27, 2021

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results

Apr 26, 2021

Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001™ for Transfusion-Dependent Beta Thalassemia

Apr 20, 2021

Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001™ in Sickle Cell Disease and Beta Thalassemia

Apr 10, 2021

CRISPR Therapeutics Presents Preclinical Data at AACR 2021 Supporting CD70 Knockout as a Novel Approach to Increasing CAR-T Cell Function

Apr 06, 2021

CRISPR Therapeutics to Participate in the 20th Annual Needham Virtual Healthcare Conference

Mar 10, 2021

CRISPR Therapeutics Announces Poster Presentation at the American Association for Cancer Research 2021 Annual Meeting

Mar 03, 2021

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Feb 16, 2021

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

Feb 05, 2021

CRISPR Therapeutics to Participate in the Guggenheim Healthcare Talks 2021 Oncology Day

Feb 01, 2021

CRISPR Therapeutics Announces the Appointment of Philippe Drouet as Chief Commercial Officer

Dec 14, 2020

CRISPR Therapeutics Receives Grant to Advance In Vivo CRISPR/Cas9 Gene Editing Therapies for HIV

Dec 05, 2020

CRISPR Therapeutics and Vertex Present New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at American Society of Hematology Annual Meeting and Exposition, Together With Publication in the New England Journal of Medicine

Dec 01, 2020

CRISPR Therapeutics and Vertex to Host Investor Webcast to Review Data Presented at the 62nd American Society of Hematology Annual (ASH) Meeting and Exposition for Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ in Sickle Cell Disease and Beta Th

Nov 24, 2020

CRISPR Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

Nov 16, 2020

CRISPR Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference

Nov 04, 2020

CRISPR/Cas9 Gene-Editing Therapy CTX001™ for Severe Hemoglobinopathies Accepted for Plenary Presentation at the 62nd American Society of Hematology (ASH) Meeting and Exposition

Oct 28, 2020

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2020 Financial Results

Oct 21, 2020

CRISPR Therapeutics Reports Positive Top-Line Results from Its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell Malignancies

Oct 07, 2020

CRISPR Therapeutics Congratulates Co-Founder Emmanuelle Charpentier on Receiving the 2020 Nobel Prize in Chemistry

Sep 29, 2020

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Sep 22, 2020

CRISPR Therapeutics and Vertex Pharmaceuticals Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency (EMA) to CTX001™ for the Treatment of Sickle Cell Disease

Sep 03, 2020

CRISPR Therapeutics to Present at the Wells Fargo 2020 Virtual Healthcare Conference

Jul 30, 2020

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Jul 27, 2020

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2020 Financial Results

Jun 30, 2020

CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares

Jun 29, 2020

CRISPR Therapeutics Announces Proposed Offering of Common Shares

Jun 25, 2020

CRISPR Therapeutics Announces the Build-Out of New Cell Therapy Manufacturing Facility

Jun 12, 2020

CRISPR Therapeutics and Vertex Announce New Clinical Data for Investigational Gene-Editing Therapy CTX001™ in Severe Hemoglobinopathies at the 25th Annual European Hematology Association (EHA) Congress

May 26, 2020

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

May 15, 2020

CRISPR Therapeutics Announces Presentations at the American Association for Cancer Research 2020 Annual Meeting

May 14, 2020

New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ for Severe Hemoglobinopathies Accepted for Oral Presentation at the 25th European Hematology Association (EHA) Congress

May 11, 2020

CRISPR Therapeutics and Vertex Pharmaceuticals Announce FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX001™ for the Treatment of Severe Hemoglobinopathies

May 07, 2020

CRISPR Therapeutics to Present at the Bank of America Securities 2020 Health Care Conference

Apr 28, 2020

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2020 Financial Results

Feb 26, 2020

CRISPR Therapeutics Proposes Changes to the Board of Directors

Feb 12, 2020

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results

Jan 06, 2020

CRISPR Therapeutics to Present at the Goldman Sachs 12th Annual Healthcare CEOs Unscripted: A View from the Top Conference

Nov 27, 2019

CRISPR Therapeutics to Present at Upcoming Investor Conferences

Nov 20, 2019

CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares

Nov 19, 2019

CRISPR Therapeutics Announces Proposed Public Offering of Common Shares

Nov 19, 2019

CRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001® for Severe Hemoglobinopathies

Oct 28, 2019

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2019 Financial Results

Oct 21, 2019

CRISPR Therapeutics and Bayer Announce an Update on Casebia Therapeutics

Oct 15, 2019

CRISPR Therapeutics and KSQ Therapeutics Announce License Agreement to Advance Companies’ Respective Cell Therapy Programs in Oncology

Oct 01, 2019

CRISPR Therapeutics to Present at Upcoming Investor Conferences

Sep 17, 2019

CRISPR Therapeutics and ViaCyte Present Positive In Vitro Data Towards a Potential Immune-Evasive Cell Replacement Therapy for Diabetes at EASD 2019

Jul 31, 2019

CRISPR Therapeutics to Present at Upcoming Investor Conferences

Jul 29, 2019

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2019 Financial Results

Jul 01, 2019

CRISPR Therapeutics Announces Oral Presentation at the 55th Annual Meeting of the European Association for the Study of Diabetes

Jun 06, 2019

Vertex Expands into New Disease Areas and Enhances Gene Editing Capabilities Through Expanded Collaboration with CRISPR Therapeutics and Acquisition of Exonics Therapeutics

May 29, 2019

CRISPR Therapeutics to Present at Upcoming Investor Conferences

May 01, 2019

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Apr 29, 2019

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2019 Financial Results

Apr 16, 2019

CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Beta Thalassemia

Apr 01, 2019

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Mar 06, 2019

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Feb 27, 2019

CRISPR Therapeutics Announces Presentations at the American Association for Cancer Research 2019 Annual Meeting

Feb 25, 2019

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results

Feb 25, 2019

CRISPR Therapeutics and Vertex Announce Progress in Clinical Development Programs for the Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001

Feb 21, 2019

CRISPR Therapeutics Proposes New Members to the Board of Directors

Feb 19, 2019

CRISPR Therapeutics and StrideBio Expand Exclusive Development and Option Agreement

Jan 22, 2019

CRISPR Therapeutics and ProBioGen Sign Collaboration and License Agreement to Develop Novel In Vivo Delivery Technologies

Jan 04, 2019

CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Sickle Cell Disease

Nov 21, 2018

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Nov 09, 2018

CRISPR Therapeutics and MaxCyte Expand Clinical and Commercial License Agreement into Oncology

Nov 07, 2018

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2018 Financial Results

Oct 10, 2018

CRISPR Therapeutics and Vertex Announce FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease

Oct 10, 2018

CRISPR Therapeutics and Vertex Announce FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease

Oct 02, 2018

CRISPR Therapeutics to Present at the Chardan Genetic Medicines Conference

Sep 20, 2018

CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares

Sep 19, 2018

CRISPR Therapeutics Announces Proposed Public Offering of Common Shares

Sep 19, 2018

CRISPR Therapeutics Announces Proposed Public Offering of Common Shares

Sep 17, 2018

CRISPR Therapeutics and ViaCyte Announce Strategic Collaboration to Develop Gene-Edited Stem Cell-Derived Therapy for Diabetes

Sep 17, 2018

CRISPR Therapeutics and ViaCyte Announce Strategic Collaboration to Develop Gene-Edited Stem Cell-Derived Therapy for Diabetes

Sep 10, 2018

CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Provide Update on U.S Federal Circuit Decision Upholding the Ruling by U.S. Patent and Trademark Office in Interference Proceeding Relating to CRISPR/Cas9 Genome Editing Technology

Aug 30, 2018

CRISPR Therapeutics to Present at Upcoming Investor Conferences

Aug 30, 2018

CRISPR Therapeutics to Present at Upcoming Investor Conferences

Aug 07, 2018

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2018 Financial Results

Aug 07, 2018

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2018 Financial Results

Jun 19, 2018

CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Announce Grant of U.S. Patent for CRISPR/Cas9 Genome Editing

Jun 05, 2018

CRISPR Therapeutics to Participate in Three June Conferences

May 30, 2018

CRISPR Therapeutics and Vertex Provide Update on FDA Review of Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease

May 15, 2018

CRISPR Therapeutics Announces Presentations at the ASGCT 21st Annual Meeting

May 08, 2018

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2018 Financial Results

May 03, 2018

CRISPR Therapeutics to Participate in May Investor Conferences

Apr 16, 2018

CRISPR Therapeutics Presents Positive Data on Allogeneic CRISPR-based CAR-T Cell Therapies at AACR 2018

Apr 13, 2018

CRISPR Therapeutics to Present Data on Allogeneic CRISPR-based CAR-T Cell Therapies at AACR 2018

Apr 04, 2018

CRISPR Therapeutics Announces the Appointment of Steve Caffé as Head of Regulatory Affairs

Mar 26, 2018

CRISPR Therapeutics Announces the Retirement of Tyler Dylan-Hyde and Appointment of Shelby Walker as Head of Intellectual Property

Mar 08, 2018

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2017 Financial Results

Feb 21, 2018

CRISPR Therapeutics to Participate in Four Upcoming Investor Conferences

Feb 08, 2018

CRISPR Therapeutics Announces Transition of Bill Lundberg, MD

Jan 04, 2018

CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares

Jan 03, 2018

CRISPR Therapeutics Announces Proposed Public Offering of Common Shares

Dec 21, 2017

CRISPR Therapeutics Announces Appointment of Dr. Rodger Novak as Chairman of the Board

Dec 12, 2017

Vertex and CRISPR Therapeutics to Co-Develop and Co-Commercialize CTX001 as CRISPR/Cas9 Gene Edited Treatment for Sickle Cell Disease and β-Thalassemia

Dec 10, 2017

CRISPR Therapeutics Announces Oral Presentation of New Data on CTX001, a CRISPR Gene-Edited Therapy for β-Thalassemia and Sickle Cell Disease, at the ASH Annual Meeting

Dec 07, 2017

CRISPR Therapeutics Submits First Clinical Trial Application for a CRISPR Gene-Edited Therapy, CTX001 in β-thalassemia

Dec 05, 2017

CRISPR Therapeutics Announces Oral Presentation of New Data on CTX001, a CRISPR Gene-Edited Medicine for β-Thalassemia and Sickle Cell Disease, at the ASH Annual Meeting

Nov 28, 2017

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Nov 13, 2017

CRISPR Therapeutics Announces Appointment of Michael Tomsicek as Chief Financial Officer

Nov 13, 2017

CRISPR Therapeutics and Casebia Collaborate with CureVac on mRNA for Gene-Editing Programs

Nov 10, 2017

CRISPR Therapeutics Highlights New Additions to Portfolio of Allogeneic CRISPR-based CAR-T Therapies at SITC Annual Meeting

Nov 08, 2017

CRISPR Therapeutics Announces Third Quarter 2017 Financial Results and Provides Business Update

Nov 07, 2017

CRISPR Therapeutics to Present New Data on Allogeneic CRISPR-based CAR-T Program and Host Investor Reception at the 32nd Annual Society for Immunotherapy of Cancer Meeting

Oct 13, 2017

CRISPR Therapeutics Awarded Grant from Friedreich’s Ataxia Research Alliance to Collaborate with University of Alabama at Birmingham on Gene-edited Treatments for Friedrich’s Ataxia

Oct 04, 2017

CRISPR Therapeutics to Present at Investor Conferences in October

Oct 02, 2017

CRISPR Therapeutics Announces Promotion of Samarth Kulkarni, Ph.D. to Chief Executive Officer

Aug 22, 2017

CRISPR Therapeutics Announces Collaboration with Massachusetts General Hospital to Research Use of CRISPR/Cas9 in T Cell Cancer Therapies

Aug 10, 2017

CRISPR Therapeutics Announces Second Quarter 2017 Financial Results and Provides Business Update

Aug 01, 2017

CRISPR Therapeutics Appoints Dr. Tony W. Ho to Head Research & Development

Jul 25, 2017

CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Appellate Brief Seeking Reversal of U.S. Patent Board Decision on CRISPR/Cas9 Gene Editing

Jul 10, 2017

CRISPR Therapeutics and Neon Therapeutics Enter Research Collaboration

Jul 05, 2017

CRISPR Therapeutics to Present at the Piper Jaffray GenomeRx Symposium

Jun 19, 2017

CRISPR Therapeutics Announces Patent for CRISPR/Cas Genome Editing in China

Jun 14, 2017

CRISPR Therapeutics to Present at the JMP Securities Life Sciences Conference

Jun 07, 2017

CRISPR Therapeutics Appoints James R. Kasinger as General Counsel

Jun 06, 2017

CRISPR Therapeutics and MaSTherCell SA sign service agreement for the development and manufacturing of allogeneic cell therapies

May 18, 2017

CRISPR Therapeutics Announces the Presentation of Data on its Lead Program at the Upcoming 22nd European Hematology Association Annual Congress

May 16, 2017

CRISPR Therapeutics and collaborators at the University of Florida awarded Target ALS Grant to develop CRISPR/Cas9-based approaches for ALS

May 12, 2017

CRISPR Therapeutics to Present at Investor Conferences in May

May 11, 2017

CRISPR Therapeutics Reports Financial Results for the Three Months Ended March 31, 2017 and Provides Business Update

May 08, 2017

CRISPR Therapeutics Announces Exclusive License of Lipid Nanoparticle Technologies Developed at MIT

May 04, 2017

CRISPR Therapeutics Appoints Samarth Kulkarni, Ph.D. as President, Expanding Role Beyond Chief Business Officer To Oversee U.S. Operations

Apr 27, 2017

CRISPR Therapeutics to Present at the 42nd Annual Deutsche Bank Health Care Conference

Apr 26, 2017

Intellia Therapeutics and CRISPR Therapeutics Announce U.S. Patent Covering CRISPR/Cas9 Ribonucleoprotein Complexes

Apr 17, 2017

CRISPR Therapeutics and Casebia Therapeutics Announce Exclusive Development and Option Agreement with StrideBio

Apr 13, 2017

CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Appeal of CRISPR/Cas9 U.S. Patent Board Decision

Mar 30, 2017

CRISPR Therapeutics to Present at the 16th Annual Needham Healthcare Conference

Mar 28, 2017

CRISPR Therapeutics Announces European Patent for CRISPR/Cas Gene Editing

Mar 14, 2017

CRISPR Therapeutics and Casebia Therapeutics Announce Commercial License Agreement With MaxCyte

Mar 10, 2017

CRISPR Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update

Mar 02, 2017

CRISPR Therapeutics to Present at the Annual Barclays Global Healthcare Conference

Feb 28, 2017

CRISPR Therapeutics Announces the Appointment of Jon Terrett, Ph.D. to Head of Immuno-Oncology Research and Translation

Feb 15, 2017

CRISPR Therapeutics to Host Conference Call and Webcast to Provide an Update on the CRISPR/Cas9 U.S. Patent Interference Proceedings and Corresponding U.K. Patents

Feb 15, 2017

CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Provide Update on CRISPR/Cas9 U.S. Patent Interference Proceedings and Grants of Corresponding Patents in the U.K.

Dec 16, 2016

CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Global Agreement on the Foundational Intellectual Property for CRISPR/Cas9 Gene Editing Technology

Nov 22, 2016

CRISPR Therapeutics to Present at the 28th Annual Piper Jaffray Healthcare Conference

Nov 21, 2016

CRISPR Therapeutics Announces Two Presentations Demonstrating the Potential for CRISPR Gene Editing To Treat Sickle Cell Disease and β-Thalassemia

Nov 08, 2016

CRISPR Therapeutics to Present at the Stifel 2016 Healthcare Conference

Nov 01, 2016

Casebia Therapeutics Press Release: Casebia Therapeutics Announces Appointment of James W. Burns, Ph.D. as President and Chief Executive Officer

Oct 18, 2016

CRISPR Therapeutics Announces Pricing of Initial Public Offering

Jun 24, 2016

CRISPR Therapeutics Raises Additional $38M as Part of Series B Financing

Jun 08, 2016

CRISPR Therapeutics and Anagenesis Biotechnologies Announce Strategic In-Licensing and Collaboration Agreement to Develop CRISPR/Cas9-based Cell Therapies for Muscle Diseases

Mar 17, 2016

CRISPR Therapeutics Adds Pablo J. Cagnoni, M.D., to Board of Directors and Names Tony Coles, M.D., Chairman of the Board to Enhance Drug Development and Commercialization Expertise

Mar 10, 2016

CRISPR Therapeutics Strengthens Its Leadership Team with the Appointment of Marc Becker as Chief Financial Officer

Dec 21, 2015

Bayer and CRISPR Therapeutics AG join Forces to Discover, Develop and Commercialize Potential Cures for Serious Genetic Diseases

Dec 18, 2015

Généthon and CRISPR Therapeutics announce Research Collaboration

Dec 11, 2015

CRISPR Therapeutics Appoints Tony Coles, M.D., to its Board of Directors

Oct 26, 2015

Vertex and CRISPR Therapeutics Establish Collaboration to Use CRISPR-Cas9 Gene Editing Technology to Discover and Develop New Treatments for Genetic Diseases

Sep 30, 2015

FierceBiotech names CRISPR Therapeutics as one of its “Fierce 15” Biotech Companies of 2015

Aug 11, 2015

CRISPR Therapeutics Bolsters Management Team with Samarth Kulkarni as Chief Business Officer and Michael Bruce as Senior Vice President, Program Portfolio and Alliance Management

Apr 29, 2015

CRISPR Therapeutics Raises Additional $64 Million to Translate Breakthrough CRISPR-Cas9 Technology into Next Generation Therapies for Patients

Apr 22, 2015

CRISPR Therapeutics Congratulates Scientific Founder Dr. Emmanuelle Charpentier on Addition to TIME Magazine’s 100 Most Influential People and Award of Louis Jeantet Prize for Medicine

Apr 07, 2015

CRISPR Therapeutics to Establish R&D Operations in Cambridge, Massachusetts

Nov 10, 2014

CRISPR Therapeutics Founding Scientist, Emmanuelle Charpentier Awarded 2015 Breakthrough Prize in Life Sciences

Apr 24, 2014

CRISPR Therapeutics Raises $25 million in Series A Financing and Announces Founding Team of World-Renowned Academics and Clinicians

You are now leaving the CRISPR Therapeutics website.

CRISPR Therapeutics is not responsible for the content or availability of third-party sites.

Continue